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Abstract
The objective of this study was to determine the prevalence of the plasmid-borne quinolone resistance genes qnrA, qnrB and qnrS in a
collection of Enterobacteriaceae causing bacteraemia. The presence of the three genes was tested for using multiplex PCR in 306 clinical
isolates. Plasmid analysis was performed using I-CeuI and S1 nuclease digestion and hybridization with speciﬁc probes for the qnr and
23S rRNA genes. Five strains were found to carry a qnr gene, one of which, qnrB16, a new variant of qnrB, was detected in a Citrobacter
freundii isolate. The qnrB6 variant was found in two C. freundii isolates and in one Citrobacter werkmanii isolate. The qnrS2 gene was found
in one Klebsiella pneumoniae isolate. The qnrA gene was not found in any of the isolates studied. The qnrS2 gene was located on a
plasmid of c. 50 kb, whereas qnrB6 and qnrB16 were inserted in the chromosome between pspF and the orf2, which had previously been
found in a complex integron. In the Hospital Clinic of Barcelona, Spain, the prevalence of qnrB was higher than that of qnrA and qnrS.
The importance of the description of the new qnrB16 is emphasized.
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Introduction
Quinolones are a group of antimicrobial agents with good
activity against Gram-negative bacteria. Quinolones act by
inhibiting the activity of type II topoisomerases (DNA gyrase
and topoisomerase IV) [1,2]. The DNA gyrase introduces
negative superhelical turns into DNA, whereas topoisomer-
ase IV relaxes DNA. Mutations in gyrA (encoding the A sub-
unit of the DNA gyrase) augment quinolone resistance,
typically four-fold to eight-fold [2,3].
Development of ﬂuoroquinolone resistance in Gram-
negative bacteria is due to two main factors: (i) mutations in
the genes encoding the drug targets; [1,2,4] and (ii) decreased
intracellular accumulation of the antimicrobial agent through
decreased cell wall permeability or overexpression of an
efﬂux pump system [1,2]. In 1998, Martı´nez-Martı´nez et al. [5]
reported that a multiresistant isolate of Klebsiella pneumoniae
from a urine culture collected in Birmingham, Alabama
contained a broad-host-range plasmid (pMG252) that, in
Escherichia coli transconjugants, increased resistance to nali-
dixic acid from 4 to 32 mg/L, and resistance to ciproﬂoxacin
from 0.008 to 0.25 mg/L. Because pMG252 did not alter host
porin expression and did not reduce quinolone accumulation,
the possibility of a novel resistance mechanism was suggested,
and the responsible gene was called qnr [5]. Qnr proteins
belong to the pentapeptide-repeat family, which is deﬁned by
a ﬁve amino acid tandem repeat with the recurrent motif
(Ser, Thr, Ala or Val)-(Asp or Asn)-(Leu or Phe)-(Ser, Thr or
Arg)-(Gly) [6]. At present, six variants of QnrA, two variants
of QnrS and 19 variants of QnrB have been described world-
wide [7].
Although the action of Qnr results in only low-level
quinolone resistance, this reduced susceptibility facilitates the
selection of mutants with higher-level resistance [5]. It is
thought that this low level of resistance to the antibacterial
agent would facilitate the occurrence of secondary mutations
and causing an increase in the level of resistance [5].
The geographical distribution of qnrA, qnrB and qnrS is
known to be wide. The spread of these and new additional qnr
genes could have a substantial impact on the treatment of
Gram-negative bacterial infections with ﬂuoroquinolones [8].
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In this study, the prevalence of the plasmid-borne quino-
lone resistance genes qnrA, qnrB and qnrS was studied in




Three hundred and six isolates of Enterobacteriaceae from
blood samples were collected between 2001 and 2002 at
the Hospital Clinic of Barcelona, Spain: 111 E. coli (36.2%),
54 K. pneumoniae (17.6%), 28 Proteus mirabilis (9.2%), 25
Enterobacter cloacae (8.2%), 22 Serratia marcescens (7.2%),
21 Salmonella enteritidis (6.9%), 16 Klebsiella oxytoca (5.2%),
eight Salmonella typhimurium (2.6%), six Enterobacter
aerogenes (2%), ﬁve Citrobacter freundii (1.6%), four
Citrobacter koseri (1.3%), three Morganella morganii (1%),
two Pantoea agglomerans (0.7%), and one Citrobacter
werkmanii (0.3%).
PCR ampliﬁcation and sequencing
Screening for qnrA, qnrB and qnrS was performed by multi-
plex PCR, using a cocktail of speciﬁc primers [9]. Bacterial
strains positive for each qnr gene were used as positive con-
trols, and were run in each batch of tested samples [10].
Positive reactions were conﬁrmed by direct sequencing of
the PCR products. To complete the sequences of the qnr
genes, an inverse PCR was performed, using DNA digested
with BfaI (New England Biolabs, Ipswich, MA, USA).
The fragments obtained were autoligated overnight at
16C using T4 Ligase (Promega Biotech Ibe´rica, Madrid,
Spain), and used as a template for a PCR with inverse
primers designed from the ampliﬁed sequences (qnrevI, 5¢-
CAGAGCCATATTTGTACCTG-3¢; and qnrevII, 5¢-GTTGG
ACAACTACCAGGCAT-3¢). The sequences obtained were
compared with those deposited in GenBank to determine
the corresponding qnr variant. The quinolone resistance-
determining region (QRDR) of gyrA and parC of the Citrobact-
er spp. isolates was sequenced directly from PCR-ampliﬁed
DNA, using the speciﬁc primers previously described [11].
To amplify the QRDR of gyrA and parC of K. pneumoniae, the
primers used were: E-1 (5¢-AAATCTGCCCGTGTCGTTG
GT-3¢) and E-2 (5¢-GCCATACCTACGGCGATACC-3¢) for
gyrA; and PARC1 (5¢-AAACCTGTTCAGCGCCGCATT-3¢)
and PARC2 (5¢-GTGGTGCCGTTAAGCAAA-3¢) for parC.
Antimicrobial susceptibility testing
MICs were determined using the Etest method, and CLSI
breakpoints were used to deﬁne susceptibility [12]. The
MICs of nalidixic acid, ciproﬂoxacin and norﬂoxacin (IZASA,
Barcelona, Spain) were determined.
Conjugation experiments
Conjugation was attempted using a liquid mating-out assay
with the reference strain E. coli J53 RifR and the C. freundii
21112 and K. pneumoniae 46408 clinical isolates. Transconju-
gants were selected on Mueller–Hinton agar plates contain-
ing rifampicin (50 mg/L) and nalidixic acid (16 mg/L).
Additionally, agar plates containing rifampicin (50 mg/L) and
ampicillin (50 mg/L) were used to search for co-transfer of
quinolone resistance, using the C. freundii 72857, C. freundii
21112 and K. pneumoniae 46408 clinical isolates as donor
strains, and E. coli J53 RifR as a recipient strain.
Plasmid DNA analysis
Plasmid DNA identiﬁcation was attempted, after digestion of
total DNA with I-CeuI and S1 nuclease, by Southern blot and
double hybridization with probes for the qnr and the 23S
rRNA (rrl gene) genes as previously described [13,14] .
Determination of the genomic surrounding of the qnrB
genes
DNA of the four qnrB-carrying Citrobacter spp. isolates was
digested with SacI (New England Biolabs), which does not
have recognition sites in the qnrB genes.
The fragments obtained were autoligated overnight at
16C using T4 DNA Ligase (Promega Biotech Ibe´rica) and
used as templates for a PCR with inverse primers designed
from the sequences obtained with the inverse PCR per-
formed with qnrevI and qnrevII to obtain the whole
sequences of qnrB6 and qnrB16 (qnrevIII, 5¢-GACATCGGT
TTAGTTTCCGG-3¢; and qnrevIV, 5¢-TCGTTCCACTTA
TCAAATAG-3¢). DNA from the resulting bands was
sequenced using the BigDye Terminator v3.1 cycle sequenc-
ing kit (Applied Biosystems, Warrington, UK).
Molecular typing
Epidemiological analysis was performed for the three qnrB-
carrying C. freundii isolates in order to assess the possible
clonality of the strains.
The analysis was performed by digestion of the chromo-
somal DNA with a restriction enzyme cutting at low fre-
quency (XbaI) followed by pulsed-ﬁeld gel electrophoresis
(PFGE) under the conditions previously described [15].
Nucleotide sequence accession number
The sequence of the qnrB16 described here has been
assigned GenBank accession number EU136183, as recom-
mended by Jacoby et al. [7].
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Results
Five of the 306 (1.6%) Enterobacteriaceae strains isolated as a
cause of bacteraemia carried a qnr gene; four of these corre-
sponded to qnrB, and one to qnrS. The qnrA gene was not
found in any of the strains studied. The qnrS gene corre-
sponded to the qnrS2 variant, and was found in a K. pneumo-
niae clinical isolate. A new variant of qnrB, named qnrB16,
was detected in C. freundii (Table 1). The amino acid
sequence of QnrB16 differed from that of QnrB1 by four
amino acids: S79A, I142M, A144T, and V212I. Furthermore,
QnrB6 and QnrB16 differed in one amino acid, A144T [7].
The QRDR of gyrA and parC of the ﬁve isolates was ampli-
ﬁed and sequenced. C. freundii 21112 showed two mutations,
one in gyrA (T83I) and one in parC (S80I). The other strains
did not show any mutation in the analysed genes. The char-
acteristics related to the presence of mutations in the target
genes, the type of qnr determinant, and the MICs of the
quinolones determined for the studied isolates are summa-
rized in Table 1.
PFGE was performed to test the possibility of a clonal
relationship among the three C. freundii clinical isolates. Fig. 1
clearly shows three different patterns of the isolates, indicat-
ing that they were not epidemiologically related; the pres-
ence and acquisition of the qnrB determinants could
therefore not be explained by vertical transmission.
Plasmids containing the qnrB genes could not be puriﬁed,
either with commercial plasmid extraction kits or the Kieser
technique [16]. This was the ﬁrst indication of a chromo-
somal location of these genes. Another approach to eluci-
date the location of the qnrB genes was the conjugation
experiment with the C. freundii 62778 clinical isolate. The
conjugation assays using both nalidixic acid and ampicillin
yielded negative results, also indicating a chromosomal
location. Plasmid analysis and hybridization experiments of
the K. pneumoniae 46408 isolate showed that qnrS2 was
located on a plasmid of c. 50 kb (Fig. 2a). Analysis of the qnrB
determinants in the other isolates by genomic mapping with
I-CeuI and S1 nuclease followed by Southern blot and double
hybridization with probes for the qnr genes and for the 23S
rRNA (rrl gene) genes (Figs 3 and 4) revealed that both
qnrB6 and qnrB16 were chromosomally located. Fig. 3 shows
the result of a mapping experiment with I-CeuI using PFGE
with pulse times ramped from 5 to 20 s for 19 h.
Although we were unable to discriminate the bands to
which the qnr probes hybridized, the sizes suggested by the
hybridization signals indicate that they derived from chromo-
somal DNA. Modiﬁcation of the PFGE conditions as previ-
ously described by Liu et al. [13] provided better resolution
of high molecular weight DNA bands (Fig. 4). The resulting
Southern blot showed that the probes for qnrB hybridized
outside the limits of the marker, i.e. above 750 kb, thereby
making the presence of a plasmid in that region impossible.
Additionally, undigested DNA from the strains C. freundii
21112 and C. werkmanii 14.0 yielded the same result when
hybridized with the qnrB probe (Fig. 5).
A region of c. 2 kb near qnrB6 and qnrB16 was sequenced
following inverse PCR. In both cases, the genomic surround-
ing was similar to that recently deposited in Genbank
(accession number AJ609296), showing a qnrB2 gene inserted




changes Qnr type MIC (mg/L)
Isolate GyrA ParC QnrB QnrS CI NA NX AM
Citrobacter
freundii 72857
– – B16 – 0.19 8 0.5 >256
C. freundii 62778 – – B6 – 0.19 8 0.25 8
C. freundii 21112 T83I S80I B6 – 3 >256 12 >256
Citrobacter
werkmanii 14.0
– – B6 – 0.09 6 0.19 16
Klebsiella
pneumoniae 46408
– – – S2 >32 >256 48 >256
CI, ciproﬂoxacin; NA, nalidixic acid; NX, norﬂoxacin; AM, ampicillin.
3 2 1 M 
FIG. 1. Pulsed-ﬁeld gel electrophoresis of the three clinical Citrobact-
er freundii isolates. DNA was digested with XbaI. M, lambda marker;
1, C. freundii 72857; 2, C. freundii 62778; 3, C. freundii 21112.
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into a class 1 integron and ﬂanked upstream by pspF and
downstream by orf2 and sapA.
Discussion
QnrA, QnrB and QnrS have been found on all continents
and in the clinically most common Enterobacteriaceae [8,17–
20]. For the ﬁrst time, a QnrS determinant has recently been
reported also in an isolate of Aeromonas spp. [17]. Several
studies carried out worldwide have shown the prevalence of
the QnrB determinants in Enterobacteriaceae [9,18,21–26]. In
Spain, several studies have shown the prevalence of qnrA and
qnrS [8,27]. In a study performed by Cano et al. [28], among
202 Enterobacter cloacae and Enterobacter aerogenes clinical
isolates, 22 Enterobacter cloacae carried the qnrS determinant.
Five different repetitive extragenic palindromic (REP)-PCR
proﬁles were obtained for the qnrS-positive Enterobacter cloa-
cae, representing 14, four, two, one and one isolate(s),
respectively. All of them were resistant to ciproﬂoxacin,
except for four isolates, clonally related according to REP-
PCR, which were susceptible to ciproﬂoxacin and to nalidixic
acid, and one isolate that was intermediately resistant to cip-
roﬂoxacin and resistant to nalidixic acid. Lavilla et al. [27]
recently analysed 305 extended-spectrum b-lactamase-
producing isolates of Enterobacteriaceae for the presence of
qnrA, qnrB and qnrS. Fifteen isolates carried a qnr determi-
nant, among which 14 carried qnrA1 and one qnrS1. The
qnr-positive strains comprised K. pneumoniae (7), Enterobacter
cloacae (6), and E. coli (2). In a recent study, three of 55
ciproﬂoxacin-resistant clinical E. coli isolates causing uncom-
plicated community-acquired cystitis were found to contain a
qnrB-like gene. This is the ﬁrst time that a QnrB determinant
has been reported in Spain [29].
In this study, we report a new variant of qnrB, qnrB16. An
interesting feature observed in the present study is the high
prevalence rate of the qnrB determinant in our hospital as
compared with those of qnrA and qnrS, and the high preva-
lence rate of qnrB in Citrobacter spp. (four of ﬁve qnr-positive
isolates). The new QnrB16 variant reported here differs
from QnrB1 [7] by four amino acids, i.e. S79A, I142M,
A144T, and V212I. They do not concern position 115, which
has been proposed as a potential point of union between
Qnr and DNA or type II topoisomerases [30]. Characteriza-
tion of the interaction of Qnr with DNA and type II topoi-
somerases is necessary for a better understanding of the
mechanism of action of Qnr and for the design of new anti-
bacterial agents able to counteract its action.
This is also the ﬁrst report of a qnrS2 determinant in a
K. pneumoniae isolate. To date, the qnrS2 gene has been
described only on a transferable IncQ-related plasmid
(pGNB2) isolated from a bacterial community in activated
sludge of a waste water treatment plant in Germany [20],
from a Salmonella enterica subsp. enterica serovar Anatum iso-
late [21], a Vibrio parahaemolyticus isolate, and an Aeromonas
punctata isolate [17].
Only the C. freundii 21112 and K. pneumoniae 46408 iso-
lates were resistant to nalidixic acid. C. freundii 21112 carried
qnrB6 and had one mutation in gyrA (T83I) and one mutation
in parC (S80I), which would explain the high MIC of nalidixic
acid (>256 mg/L) and also the MIC of ciproﬂoxacin (3 mg/L).
K. pneumoniae 46408 carried qnrS2, but no mutations were
found in any of the studied genes (gyrA and parC). A Salmo-
nella isolate carrying qnrS2 showed MICs of 0.5 and 16 mg/L
of ciproﬂoxacin and nalidixic acid, respectively [21]. More-
over, a qnrS2 determinant found in an A. punctata isolate [17]
was transferred to E. coli TOP10, conferring low levels of
resistance to ﬂuoroquinolones, with MICs of nalidixic acid
from 1 to 4 mg/mL, and MICs of ciproﬂoxacin from <0.01to
(a) (b) (c) 
M  1  2  1 2 1 2 
FIG. 2. Plasmid identiﬁcation in Klebsiella pneumoniae 46408 by
genomic mapping with I-CeuI and digestion with S1 nuclease. (a)
Pulsed-ﬁeld gel electrophoresis (PFGE). Lane M: lambda ladder PFGE
marker. Lane 1: digestion with I-CeuI. Lane 2: digestion with S1
nuclease. (b) Digestion with I-CeuI. Lane 1: hybridization with a 23S
rRNA gene probe. Lane 2: hybridization with a qnrS probe. (c)
Digestion with S1 nuclease. Lane 1: hybridization with a 23S rRNA
gene probe. Lane 2: hybridization with a qnrS probe. Arrows indicate
plasmid location.
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0.25 mg/mL. As no mutations in gyrA and parC were found,
the high levels of resistance to nalidixic acid (>256 mg/L) and
ciproﬂoxacin (>32 mg/L) in this K. pneumoniae isolate could
have been achieved by the combination of the qnrS2 determi-
nant and some other mechanism of quinolone resistance,
such as changes in permeability (associated with a decrease
in porin expression or overexpression of efﬂux pump
systems) for these antimicrobial agents, or the recently
reported mechanisms encoded by aac(6¢)-Ib-cr and/or qepA
[31,32]. In the remaining qnr-positive isolates, and as
reported previously, the Qnr determinant alone did not
confer resistance to ﬂuoroquinolones [33–35].
The origin of Qnr has been identiﬁed in several genomes
(Shewanella algae and Vibrio-like species) [36]. In some cases,
qnr-like genes have been proposed to be inserted in the
chromosome of bacterial species that do not naturally pos-
sess qnr-like genes [22,37,38]. Repeated plasmid puriﬁcation
and conjugation experiments using E. coli J53RifR yielded neg-
ative results concerning the presence of qnr-containing plas-
mids. Genomic mapping analysis with I-CeuI and S1 nuclease
1 2 3  4 1  2 3  4  1  2  3 4  1 2  3 4  M  1  2  3  4  1  2  3  4  
    (a1) (a2) (b1) (b2) (c1) (c2) 
FIG. 3. Genomic localization of qnrB by genomic mapping with I-CeuI and digestion with S1 nuclease. (a) Pulsed-ﬁeld gel electrophoresis (PFGE).
A1, digestion with I-CeuI; A2, digestion with S1 nuclease. (b) Digestion with I-CeuI. B1, hybridization with a probe for the 23S rRNA gene; B2,
hybridization with a qnrB probe. (c) Digestion with S1 nuclease. C1, hybridization with a 23S rRNA gene probe; C2, hybridization with a qnrB
probe. Lane M: lambda ladder PFGE marker. Lane 1: Citrobacter freundii 72857. Lane 2: C. freundii 62778. Lane 3. C. freundii 21112. Lane 4: Citrob-
acter werkmanii 14.0. The rectangle in A1 covers the fragments shown in Fig. 4 after changing the PFGE conditions. The arrow represents the
slowest-moving band of the lambda ladder (727.5 kb).
(b) 
1  2 3 4  
(c) 
1 2  3 
(a) 
1  2  3  4 4 
FIG. 4. Localization of qnrB on I-CeuI-digested DNA following pulsed-ﬁeld gel electrophoresis (PFGE) under the conditions described by Liu
et al. [13] (a) PFGE. (b) Hybridization with a 23S rRNA gene probe. (c) Hybridization with a qnrB probe. Lane 1: Citrobacter freundii 72857. Lane 2:
C. freundii 62778. Lane 3: C. freundii 21112. Lane 4: Citrobacter werkmanii 14.0. The arrow indicates the position of the slowest-moving band of
the lambda ladder (727.5 kb).
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followed by Southern blot hybridization studies conﬁrmed
these results, which point to the chromosomal location of
these genes. Although plasmids larger than 750 kb have been
described (http://www.ncbi.nlm.nih.gov/genomes/genlist.cgi?
taxid=1&type=7&name=Plasmids), their occurrence is rare,
and they have been found only in bacteria with special
requirements and from extreme environments. Therefore,
the data presented here are taken to demonstrate the chro-
mosomal location of qnrB6 in C. freundii and C. werkmanii and
of qnrB16 in C. freundii.
On the other hand, variants of qnrA, and in some cases
qnrB, have been found as part of a complex class of type 1
integrons containing a presumed recombinase, Orf513
[39,40]. However, in the few qnrS-bearing plasmids
sequenced, qnrS was not part of an integron, although one
plasmid was ﬂanked by inverted repeats with an insertion
sequence-like structure that could have been responsible for
its mobilization [21]. The qnrB determinants described in this
study were found to be associated with an integron-like
structure similar to that reported for a qnrB2 gene in K. pneu-
moniae [41].
As new variants of Qnr determinants continuously appear
in different genomic locations and also outside the Enterobac-
teriaceae family, further studies are necessary to determine
the extent of their distribution and to assess their clinical
implications as contributors to quinolone resistance.
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